MedImmune to expand with $250M manufacturing plant

Published



Washington’s most-successful biotech company, MedImmune, will break ground today on a $250 million manufacturing plant in Frederick. The expansion, which will increase the Gaithersburg-based firm’s capacity to produce a number of therapeutics, is the next step in the evolution of the Washington region’s maturing biotech industry, officials said.

MedImmune’s expansion “is important. All of this is evolutionary,” said Aris Melissaratos, Maryland’s secretary of business and economic development. “For every drug in the pipeline, you want to get [to the manufacturing stage].”

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.